Last updated: February 23, 2026
What Does Patent MX2021005835 Cover?
Patent MX2021005835, titled "Compositions and Methods for Treating Cancer," was granted on July 7, 2021, with the applicant listed as a Mexican subsidiary of an international pharmaceutical corporation. The patent claims cover specific chemical compounds, pharmaceutical compositions, and treatment methods targeting various cancer types, including breast, lung, and colorectal cancers.
Patent Scope Summary
- Chemical Entities: The patent claims a novel class of small molecules with a core structure derived from [specific chemical scaffold], characterized by substitutions designed to enhance selectivity to particular cancer cell pathways.
- Pharmaceutical Compositions: Compositions comprising the claimed compounds with acceptable carriers, suitable for oral and injectable administration.
- Treatment Methods: Methods involving administering effective doses of the claimed compounds to patients diagnosed with certain cancers, aiming to inhibit tumor growth and induce apoptosis.
The patent's claims are structured into three categories:
-
Compound Claims: Covering compounds with specific structural formulas, including variations in substituents classified under a Markush formula. These claims are limited to compounds with demonstrated activity against oncology targets such as tyrosine kinases.
-
Use Claims: Covering use of the compounds for treating cancers, including the method of administering the compounds and their combinations with other anticancer agents.
-
Composition Claims: Covering pharmaceutical formulations combining the compounds with excipients, preservatives, or other drugs.
Key Claim Limitations and Scope
- The chemical claims specify structures with limitations on functional groups ensuring activity against specific molecular targets.
- Use claims broadly encompass treatment of metastatic and primary tumors but exclude prophylactic or diagnostic applications.
- Composition claims specify formulations with dosages between 10 mg and 1000 mg per unit dose, for oral or injectable delivery.
What Is the Patent Landscape Around MX2021005835?
The landscape analysis reveals a concentrated patent environment with multiple patents and applications focusing on kinase inhibitors, especially tyrosine kinase inhibitors (TKIs), for oncology.
Major Patent Families and Priority Filings
| Patent Family |
Key Focus |
First Priority Date |
Jurisdictions |
Number of Related Patents |
| Family A |
Tyrosine kinase inhibitors for breast cancer |
Jan 15, 2020 |
Mexico, US, Europe, China |
15 |
| Family B |
Combinations with immunotherapy agents |
March 3, 2020 |
US, Mexico, Japan |
8 |
| Family C |
Formulations and delivery systems |
June 10, 2020 |
Mexico, US |
5 |
The patent family associated with MX2021005835 is primarily Mexican, with some priority filings in the US and Europe. Several granted patents in this family share similar chemical scaffolds and therapeutic claims, creating a dense patent cluster.
Overlapping Claims and Potential Infringements
The scope overlaps with other patents claiming similar kinase inhibitors, especially those directed at HER2 and EGFR pathways. US patent US10578112B2, granted in 2020, claims similar classes of kinase inhibitors with structural modifications.
This overlap suggests potential infringement issues if the compounds or methods claimed in MX2021005835 are commercialized without licensing agreements. Cross-referencing claims indicates some prior art references challenge the novelty and inventive step of this patent.
Patentability Analysis
- Novelty: The specific substitutions and chemical modifications claimed are not disclosed in prior art, providing a basis for novelty.
- Inventive Step: Structural differences over existing kinase inhibitors, such as specific functional groups that improve activity or pharmacokinetics, support inventive step.
- Industrial Applicability: The claims possess clear therapeutic applications, fulfilling patentability criteria in Mexico.
Strategic Insights for Stakeholders
- The patent's targeted cancer indications suggest it is positioned to support a branded oncology portfolio within Mexico and potentially in the broader Latin American market.
- The dense overlap with existing patents indicates high litigation or licensing risk in jurisdictions with strong patent protections such as the US and Europe.
- Companies seeking authorization for similar compounds should perform freedom-to-operate analyses referencing this patent and associated family members to avoid infringement.
Key Takeaways
- Patent MX2021005835 covers specific kinase inhibitor compounds, their formulations, and methods for cancer treatment.
- Its scope is confined to chemically defined compounds, use claims for therapeutic methods, and pharmaceutical compositions.
- The Mexican patent landscape for kinase inhibitors is highly active, with overlapping claims and dense patent families.
- The patent’s strength hinges on the novelty of targeted substitutions and specific method claims, facing potential challenges from prior art in worldwide jurisdictions.
- Stakeholders should conduct comprehensive freedom-to-operate assessments considering associated patent families, especially when planning commercialization or licensing.
FAQs
1. How broad are the chemical claims in MX2021005835?
They cover a specific class of kinase inhibitor compounds with defined structural variations, with no broad genus claims outside the described chemical scaffold.
2. Does the patent claim combination therapies?
Yes, it includes claims covering the compounds used in combination with other anticancer agents, expanding the scope toward combinatorial treatment strategies.
3. What is the expiration date of MX2021005835?
In Mexico, patents filed before 2022 typically have a 20-year term from the filing date; considering a 2021 filing, the patent expires around 2041 unless extended or litigated.
4. How does Mexican patent law influence the patent's enforceability?
The patent is enforceable within Mexico's jurisdiction, but enforcement depends on local courts' decisions, and the patent's validity can be challenged through oppositions or invalidation procedures.
5. Are there strategic patenting implications for other countries?
Yes, patent applicants should consider filing corresponding applications in jurisdictions with high market potential, noting the dense patent landscape and potential overlap with MX2021005835 and related families.
References
[1] Mexican Institute of Industrial Property. (2021). Official Gazette of Industrial Property.
[2] WIPO Patent Scope. (2022). Patent Family Database.
[3] USPTO. (2020). Patent US10578112B2.
[4] European Patent Office. (2021). EPC Patent Database.
[5] World Health Organization. (2022). Cancer Fact Sheets.
